[HTML][HTML] Erlotinib as second‑or third‑line treatment in elderly patients with advanced non‑small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
M Miyawaki, K Naoki, S Yoda… - Molecular and …, 2017 - spandidos-publications.com
The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
Y Togashi, H Hayashi, K Nakagawa… - Drug design …, 2014 - Taylor & Francis
Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …
[HTML][HTML] EGFR 野生型晚期非小细胞肺癌的治疗进展
马峰， 史晓宇， 孟玮， 张敬， 赵丽霞… - Chinese Journal of …, 2014 - ncbi.nlm.nih.gov
肺癌是癌症死亡的主要原因。 肺癌的治疗仍是医疗界最具挑战性的任务之一。
表皮生长因子受体酪氨酸激酶抑制剂（ epidermal growth factor receptor-tyrosine kinase …
表皮生长因子受体酪氨酸激酶抑制剂（ epidermal growth factor receptor-tyrosine kinase …
[HTML][HTML] The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second-or third-line for advanced non-small-cell lung cancer patients with wild …
G Bronte, T Franchina, M Alù, G Sortino, C Celesia… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background Second-line treatment for advanced non-small-cell lung cancer (NSCLC)
patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine …
patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine …
Personalized targeted therapy for lung cancer
K Wu, L House, W Liu, WCS Cho - Zhongguo Fei Ai Za Zhi, 2013 - search.proquest.com
由于每一肺癌患者在临床特征, 预后, 治疗反应和耐受性方面的进展都是独特的,
所以肺癌被认为是异质性疾病. 个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗 …
所以肺癌被认为是异质性疾病. 个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗 …
[PDF][PDF] Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer …
J Maneechawakajorn, S Hathaisanguan - J Med Assoc Thai, 2016 - thaiscience.info
Background: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly
treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and …
treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and …
Treatment progress for EGFR wild-type advanced non-small cell lung cancer
MA Feng, SHI Xiaoyu, M Wei, J Zhang… - Zhongguo Fei Ai …, 2014 - search.proquest.com
肺癌是癌症死亡的主要原因. 肺癌的治疗仍是医疗界最具挑战性的任务之一.
表皮生长因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor-tyrosine kinase …
表皮生长因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor-tyrosine kinase …
[HTML][HTML] Inibidores das tirosinacinases na terapêutica farmacológica
S Saraiva, S Morgado, M Morgado - Revista Portuguesa de …, 2013 - farmacoterapia.pt
A descoberta de mutações em tirosinacinases (TK) envolvidas na patogénese de diversas
patologias, nomeadamente oncológicas, levou à investigação de inibidores das …
patologias, nomeadamente oncológicas, levou à investigação de inibidores das …
İleri evre küçük hücreli dışı akciğer kanserli hastalarda erlotinib tedavisinin etkinliği
A Ayyıldız - 2013 - search.proquest.com
Akciğer kanseri, günümüzde kansere bağlı ölümlerin tüm dünyadaki en yaygın nedenidir.
Akciğer kanseri olgularının yaklaşık% 80‟ ini küçük hücreli dışı akciğer kanseri (KHDAK) …
Akciğer kanseri olgularının yaklaşık% 80‟ ini küçük hücreli dışı akciğer kanseri (KHDAK) …